Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958776 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2POLBALDH1A1LMNACYP1A2 | |
| SCHEMBL3792050 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2POLBALDH1A1LMNACYP1A2 | |
| SCHEMBL2897289 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2POLBALDH1A1LMNACYP1A2 | |
| SCHEMBL17509879 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2POLBALDH1A1LMNACYP1A2 | |
| SCHEMBL21399858 | 0.84 | CNR1 (0.49) | ALDH1A1CNR1 | |
| SCHEMBL12283613 | 0.83 | CYP1A2 (0.46) | SMN1; SMN2POLBALDH1A1LMNACYP1A2 | |
| SCHEMBL1312687 | 0.83 | ACACB (0.55) | ALDH1A1CNR1 | |
| SCHEMBL21399933 | 0.83 | CNR1 (0.48) | SMN1; SMN2ALDH1A1CNR1 | |
| SCHEMBL1312484 | 0.83 | ACACB (0.55) | ALDH1A1CNR1 | |
| SCHEMBL1312488 | 0.83 | ACACB (0.55) | ALDH1A1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559505-B2 | IDH mutant inhibitor and use thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2026-02-24 | — | — | US | disclosed |
| US-20250049809-A1 | INHIBITORS OF MUTANT IDH1 AND IDH2 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-02-13 | — | — | US | disclosed |
| US-20240208978-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4356914-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2024-04-24 | — | — | EP | disclosed |
| CN-117460512-A | IDH mutant inhibitors and uses thereof | 微境生物医药科技(上海)有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20230174550-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-06-08 | — | — | US | disclosed |
| US-11649247-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | ELI LILLY AND COMPANY (US) | 2023-05-16 | — | — | US | disclosed |
| US-11629156-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | ELI LILLY AND COMPANY (US) | 2023-04-18 | — | — | US | disclosed |
| EP-3763717-B1 | PYRIDO[4,3-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | LILLY CO ELI (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115768775-A | IDH mutant inhibitor and application thereof | 微境生物医药科技(上海)有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-2183228-B1 | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-8575156-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8487094-B2 | Synthesis of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8329897-B2 | Synthesis of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| EP-2183229-B1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS INC (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20110269957-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| CN-102105454-A | Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 | BOEHRINGER INGELHEIM INT | 2011-06-22 | — | — | CN | disclosed |
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals ,Inc. | 2011-01-20 | — | — | US | disclosed |
| US-20100256363-A1 | SYNTHESIS OF INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649247-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | IDH2, IDH1, IDH3B | SMN1; SMN2 1581/4885POLB 616/4885ALDH1A1 66/4885 |
| US-12559505-B2 | IDH mutant inhibitor and use thereof | IDH3A, IDH1, IDH3B | SMN1; SMN2 2259/4885POLB 2987/4885ALDH1A1 291/4885 |
| US-20110269957-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | SMN1; SMN2 2728/4885POLB 678/4885ALDH1A1 345/4885 |
| US-11629156-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | IDH2, IDH1, IDH3B | SMN1; SMN2 1581/4885POLB 616/4885ALDH1A1 66/4885 |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | P2RX5, P2RX3, ABCG2 | SMN1; SMN2 4388/4885POLB 2247/4885ALDH1A1 388/4885 |
| US-20100256363-A1 | SYNTHESIS OF INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD11B2, HSD17B1 | SMN1; SMN2 2752/4885POLB 807/4885ALDH1A1 399/4885 |
| US-20230174550-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | IDH1, IDH3A, IDH3B | SMN1; SMN2 3476/4885POLB 2532/4885ALDH1A1 123/4885 |
| US-20250049809-A1 | INHIBITORS OF MUTANT IDH1 AND IDH2 | IDH1, IDH2, IDH3A | SMN1; SMN2 753/4885POLB 2177/4885ALDH1A1 709/4885 |
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | SMN1; SMN2 3642/4885POLB 1461/4885ALDH1A1 98/4885 |
| US-20240208978-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | IDH1, IDH3A, IDH3B | SMN1; SMN2 3451/4885POLB 2277/4885ALDH1A1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.